Vanilloid Receptor TRPV1 Antagonists as the Next Generation of Painkillers. Are We Putting the Cart before the Horse?

This publication has 30 references indexed in Scilit:

• Increased Expression of Vanilloid Receptor 1 on Myelinated Primary Afferent Neurons Contributes to the Antihyperalgesic Effect of Capsaicin Cream in Diabetic Neuropathic Pain in Mice
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• A Modular PIP ₂ Binding Site as a Determinant of Capsaicin Receptor Sensitivity
  Science, 2003
• Endocannabinoids Induce Ileitis in Rats via the Capsaicin Receptor (VR1)
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• Vanilloid (Capsaicin) Receptors in Health and Disease
  American Journal of Clinical Pathology, 2002
• Molecular Basis for Species-Specific Sensitivity to “Hot” Chili Peppers
  Cell, 2002
• Functional Properties of the High-Affinity TRPV1 (VR1) Vanilloid Receptor Antagonist (4-Hydroxy-5-iodo-3-methoxyphenylacetate ester) Iodo-Resiniferatoxin
  The Journal of Pharmacology and Experimental Therapeutics, 2002
• Small-molecule neuropeptide Y Y5 antagonists
  Drugs of the Future, 2002
• The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway
  Annual Review of Neuroscience, 2001
• Ruthenium red as a capsaicin antagonist
  Life Sciences, 1991